226 related articles for article (PubMed ID: 35128648)
1. Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients.
Indirli R; Bandera A; Valenti L; Ceriotti F; Di Modugno A; Tettamanti M; Gualtierotti R; Peyvandi F; Montano N; Blasi F; Costantino G; Resi V; Orsi E; Arosio M; Mantovani G; Ferrante E;
Eur J Clin Invest; 2022 May; 52(5):e13753. PubMed ID: 35128648
[TBL] [Abstract][Full Text] [Related]
2. Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study.
Dres M; Hausfater P; Foissac F; Bernard M; Joly LM; Sebbane M; Philippon AL; Gil-Jardiné C; Schmidt J; Maignan M; Treluyer JM; Roche N
Int J Chron Obstruct Pulmon Dis; 2017; 12():1047-1056. PubMed ID: 28408815
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis.
Bernal-Morell E; García-Villalba E; Vera MDC; Medina B; Martinez M; Callejo V; Valero S; Cinesi C; Piñera P; Alcaraz A; Marin I; Muñoz A; Cano A
J Infect; 2018 Mar; 76(3):249-257. PubMed ID: 29246637
[TBL] [Abstract][Full Text] [Related]
4. The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study.
Gregoriano C; Koch D; Kutz A; Haubitz S; Conen A; Bernasconi L; Hammerer-Lercher A; Saeed K; Mueller B; Schuetz P
Clin Chem Lab Med; 2021 Apr; 59(5):995-1004. PubMed ID: 33554516
[TBL] [Abstract][Full Text] [Related]
5. The kinetic profiles of copeptin and mid regional proadrenomedullin (MR-proADM) in pediatric lower respiratory tract infections.
Baumann P; Fuchs A; Gotta V; Ritz N; Baer G; Bonhoeffer JM; Buettcher M; Heininger U; Szinnai G; Bonhoeffer J;
PLoS One; 2022; 17(3):e0264305. PubMed ID: 35271609
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Mid-Region Proadrenomedullin and In Vitro Interferon Gamma Production for In-Hospital Mortality in Patients with COVID-19 Pneumonia and Respiratory Failure: An Observational Prospective Study.
Mangioni D; Oggioni M; Chatenoud L; Liparoti A; Uceda Renteria S; Alagna L; Biscarini S; Bolis M; Di Modugno A; Mussa M; Renisi G; Ungaro R; Muscatello A; Gori A; Ceriotti F; Bandera A
Viruses; 2022 Jul; 14(8):. PubMed ID: 36016305
[TBL] [Abstract][Full Text] [Related]
7. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study.
Christ-Crain M; Morgenthaler NG; Struck J; Harbarth S; Bergmann A; Müller B
Crit Care; 2005; 9(6):R816-24. PubMed ID: 16356231
[TBL] [Abstract][Full Text] [Related]
8. High levels of mid-regional proadrenomedullin in ARDS COVID-19 patients: the experience of a single, Italian Center.
Benedetti I; Spinelli D; Callegari T; Bonometti R; Molinaro E; Novara E; Cassinari M; Frino C; Guaschino R; Boverio R; Lauritano EC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1743-1751. PubMed ID: 33629344
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic value of MR-pro ADM, procalcitonin, and copeptin in sepsis.
Cander B; Visneci EF; Karaoglan O; Cakmak F; Tuncar A; Taslidere B
Open Med (Wars); 2023; 18(1):20230865. PubMed ID: 38223899
[TBL] [Abstract][Full Text] [Related]
10. Systematic review with meta-analysis of mid-regional pro-adrenomedullin (MR-proadm) as a prognostic marker in Covid-19-hospitalized patients.
Fialek B; De Roquetaillade C; Pruc M; Navolokina A; Chirico F; Ladny JR; Peacock FW; Szarpak L
Ann Med; 2023 Dec; 55(1):379-387. PubMed ID: 36607317
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.
Suberviola B; Castellanos-Ortega A; Llorca J; Ortiz F; Iglesias D; Prieto B
Swiss Med Wkly; 2012; 142():w13542. PubMed ID: 22430899
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of mid-regional proadrenomedullin levels in the resuscitation phase of severely burned patients and its utility in early sepsis detection.
Flores E; Estébanez B; Quintana M; Fernández-Puntero B; Nanwani K; Cachafeiro L; Martínez JR; Agrifoglio A; Sánchez-Sánchez M
Burns; 2024 Aug; 50(6):1519-1527. PubMed ID: 38570251
[TBL] [Abstract][Full Text] [Related]
13. Superior accuracy of mid-regional proadrenomedullin for mortality prediction in sepsis with varying levels of illness severity.
Andaluz-Ojeda D; Nguyen HB; Meunier-Beillard N; Cicuéndez R; Quenot JP; Calvo D; Dargent A; Zarca E; Andrés C; Nogales L; Eiros JM; Tamayo E; Gandía F; Bermejo-Martín JF; Charles PE
Ann Intensive Care; 2017 Dec; 7(1):15. PubMed ID: 28185230
[TBL] [Abstract][Full Text] [Related]
14. Does mid-regional pro-adrenomedullin (MR-proADM) improve the sequential organ failure assessment-score (SOFA score) for mortality-prediction in patients with acute infections? Results of a prospective observational study.
Haag E; Gregoriano C; Molitor A; Kloter M; Kutz A; Mueller B; Schuetz P
Clin Chem Lab Med; 2021 May; 59(6):1165-1176. PubMed ID: 33554514
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of mid-regional pro-adrenomedullin, compared to other biomarkers (including lymphocyte subpopulations and immunoglobulins), as a prognostic biomarker in COVID-19 critically ill patients: New evidence from a 15-month observational prospective study.
Montrucchio G; Sales G; Balzani E; Lombardo D; Giaccone A; Cantù G; D'Antonio G; Rumbolo F; Corcione S; Simonetti U; Bonetto C; Zanierato M; Fanelli V; Filippini C; Mengozzi G; Brazzi L
Front Med (Lausanne); 2023; 10():1122367. PubMed ID: 37035317
[TBL] [Abstract][Full Text] [Related]
16. Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullin.
Sozio E; Moore NA; Fabris M; Ripoli A; Rumbolo F; Minieri M; Boverio R; Rodríguez Mulero MD; Lainez-Martinez S; Martínez Martínez M; Calvo D; Gregoriano C; Williams R; Brazzi L; Terrinoni A; Callegari T; Hernández Olivo M; Esteban-Torrella P; Calcerrada I; Bernasconi L; Kidd SP; Sbrana F; Miguens I; Gordon K; Visentini D; Legramante JM; Bassi F; Cortes N; Montrucchio G; Di Lecce VN; Lauritano EC; García de Guadiana-Romualdo L; González Del Castillo J; Bernal-Morell E; Andaluz-Ojeda D; Schuetz P; Curcio F; Tascini C; Saeed K
Respir Res; 2022 Aug; 23(1):221. PubMed ID: 36031619
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19.
Lo Sasso B; Gambino CM; Scichilone N; Giglio RV; Bivona G; Scazzone C; Muratore R; Milano S; Barbagallo M; Agnello L; Ciaccio M
Lab Med; 2021 Sep; 52(5):493-498. PubMed ID: 33928380
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission.
Gonzalez Del Castillo J; Wilson DC; Clemente-Callejo C; Román F; Bardés-Robles I; Jiménez I; Orviz E; Dastis-Arias M; Espinosa B; Tornero-Romero F; Giol-Amich J; González V; Llopis-Roca F;
Crit Care; 2019 Oct; 23(1):335. PubMed ID: 31665092
[TBL] [Abstract][Full Text] [Related]
19. Mid-Regional Pro-Adrenomedullin Can Predict Organ Failure and Prognosis in Sepsis?
Spoto S; Basili S; Cangemi R; D'Avanzo G; Lupoi DM; Romiti GF; Argemi J; Yuste JR; Lucena F; Locorriere L; Masini F; Testorio G; Calarco R; Fogolari M; Francesconi M; Battifoglia G; Costantino S; Angeletti S
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139258
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study.
Montrucchio G; Sales G; Rumbolo F; Palmesino F; Fanelli V; Urbino R; Filippini C; Mengozzi G; Brazzi L
PLoS One; 2021; 16(2):e0246771. PubMed ID: 33556140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
